Bottom line
RYCFX vs FBIOX: the short answer
RYCFX (Biotechnology Fund) and FBIOX (Biotechnology Portfolio) are both mutual funds.
But FBIOX is far broader, holding 215 positions to 74 for RYCFX, so beyond the top names it adds exposure RYCFX doesn't have.
FBIOX is cheaper at 0.62% vs 2.38% — a difference of $176 a year per $10,000 invested.
Over five years, FBIOX returned +3.5% a year vs +3.0% for RYCFX (reporting dates differ).
Updated Nov 19, 2026
RYCFX vs FBIOX side by side
| RYCFX | FBIOX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Guggenheim | Fidelity |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 2.38% | 0.62% |
| Annual cost per $10k | $238 | $62 |
| 10-yr cost on $10k (prospectus) | $2,763 | $774 |
| Max front load | 0% | — |
| 12b-1 fee | 1% | 0% |
| 1-yr return | +28.4% | +36.4% |
| 5-yr return (annualized) | +3.0% | +3.5% |
| 10-yr return (annualized) | +4.8% | +6.9% |
| Best quarter | +28.0% | +33.6% |
| Worst quarter | −22.7% | −28.4% |
| Net assets (fund) | $136.8M | $5.3B |
| Number of holdings | 74 | 215 |
| Portfolio turnover | 75% | 45% |
| Returns as of | Dec 31, 2025 | Apr 30, 2026 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RYCFX | FBIOX | Difference |
|---|---|---|---|
| 2025 | +29.4% | +36.4% | −7.0% |
| 2024 | −1.7% | +7.3% | −9.0% |
| 2023 | +5.0% | +10.1% | −5.1% |
| 2022 | −13.9% | −15.9% | +1.9% |
| 2021 | +0.8% | −12.4% | +13.2% |
| 2020 | +20.9% | +38.3% | −17.5% |
| 2019 | +23.8% | +36.0% | −12.2% |
| 2018 | −9.9% | −10.7% | +0.8% |
| 2017 | +28.4% | +27.9% | +0.6% |
| 2016 | −20.3% | −23.7% | +3.4% |
Source: Fund prospectus bar charts
Holdings overlap
13 of RYCFX's top 25 holdings also appear in FBIOX's top 25.
| Holding | RYCFX | FBIOX |
|---|---|---|
| Abbvie Inc | 8.17% | 9.22% |
| Amgen Inc | 5.05% | 6.53% |
| Gilead Sciences Inc | 4.49% | 4.82% |
| Revolution Medicines Inc | 2.48% | 2.02% |
| Alnylam Pharmaceuticals Inc | 2.36% | 2.93% |
| Moderna Inc | 2.15% | 1.28% |
| Biogen Inc | 2.13% | 1.26% |
| Natera Inc | 2.12% | 1.41% |
| Insmed Inc | 1.79% | 2.25% |
| Roivant Sciences Ltd | 1.66% | 1.13% |
| Argenx Se | 1.48% | 2.25% |
| Jazz Pharmaceuticals Plc | 1.42% | 1.84% |
| Bridgebio Pharma Inc | 1.38% | 0.89% |
Source: SEC Form N-PORT
RYCFX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
FBIOX top 10
- Krystal Biotech Inc — 10.58%
- Abbvie Inc — 9.22%
- Amgen Inc — 6.53%
- Gilead Sciences Inc — 4.82%
- Fidelity Revere Street Trust — 3.35%
- Alnylam Pharmaceuticals Inc — 2.93%
- Praxis Precision Medicines Inc. — 2.47%
- Insmed Inc — 2.25%
- Argenx Se — 2.25%
- Ascendis Pharma A/s — 2.04%
FAQ
What is the difference between RYCFX and FBIOX?
Which is cheaper, RYCFX or FBIOX?
Should I own both RYCFX and FBIOX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.